BACKGROUND: The pentavalent antimonials are considered the first-choice drugs for treatment of leishmaniasis. Intralesional therapy is used to minimize the systemic effects of the drug. METHODS: Seventy patients were treated with weekly intralesional infiltrations of Glucantime(®) (meglumine antimoniate) for cutaneous leishmaniasis. Nine of them had infiltrated itchy erythematous and vesiculous plaques at the injection sites. Cutaneous tests were undertaken in eight patients. RESULTS: Prick tests were negative and seven of the eight patients showed positive intradermal tests with Glucantime(®) dilutions reading at D2 and D4. Only one patient had positive patch test to Glucantime a.i. Local reactions at the site of injection have been briefly mentioned in some reported series of leishmaniasis treated with intralesional or intramuscular meglumine antimoniate but the mechanism has never been explained before. CONCLUSIONS: We report the first series of patients with local reactions at the injection sites of meglumine antimoniate in whom type IV hypersensitivity could be involved.
BACKGROUND: The pentavalent antimonials are considered the first-choice drugs for treatment of leishmaniasis. Intralesional therapy is used to minimize the systemic effects of the drug. METHODS: Seventy patients were treated with weekly intralesional infiltrations of Glucantime(®) (meglumine antimoniate) for cutaneous leishmaniasis. Nine of them had infiltrated itchy erythematous and vesiculous plaques at the injection sites. Cutaneous tests were undertaken in eight patients. RESULTS: Prick tests were negative and seven of the eight patients showed positive intradermal tests with Glucantime(®) dilutions reading at D2 and D4. Only one patient had positive patch test to Glucantime a.i. Local reactions at the site of injection have been briefly mentioned in some reported series of leishmaniasis treated with intralesional or intramuscular meglumine antimoniate but the mechanism has never been explained before. CONCLUSIONS: We report the first series of patients with local reactions at the injection sites of meglumine antimoniate in whom type IV hypersensitivity could be involved.
Authors: Erica de Camargo Ferreira e Vasconcellos; Maria Inês Fernandes Pimentel; Cláudia Maria Valete-Rosalino; Maria de Fátima Madeira; Armando de Oliveira Schubach Journal: Rev Inst Med Trop Sao Paulo Date: 2014 Jul-Aug Impact factor: 1.846
Authors: Carla Oliveira-Ribeiro; Maria Inês Fernandes Pimentel; Liliane de Fátima Antonio Oliveira; Érica de Camargo Ferreira E Vasconcellos; Fatima Conceição-Silva; Armando de Oliveira Schubach; Aline Fagundes; Cintia Xavier de Mello; Eliame Mouta-Confort; Luciana de Freitas Campos Miranda; Claudia Maria Valete-Rosalino; Ana Cristina da Costa Martins; Raquel de Vasconcellos Carvalhaes de Oliveira; Leonardo Pereira Quintella; Marcelo Rosandiski Lyra Journal: PLoS Negl Trop Dis Date: 2021-09-23